In short
Clinical trials investigating Gr0015 are studying its use in adults with alpha-1 antitrypsin deficiency-related lung disease and/or liver disease. The trials aim to evaluate safety, tolerability, and early signs of efficacy in Phase 1/2 research.
Key points
- Clinical trials investigating Gr0015 are focused on adults with alpha-1 antitrypsin deficiency-associated lung disease and/or liver disease. The study is a Phase 1/2 trial, so it first looks at safety and tolerability and then at early signs of effect. The Phase 1 part measures treatment-emergent adverse events and serious adverse events. The Phase 2 part measures blood levels of total AAT, Z-AAT, and M-AAT. The trial is authorised and plans to enroll 184 participants.
Trial overview
This clinical trial is an interventional study, which means the research team gives the study treatment and then measures the results. The study is authorised and is evaluating Gr0015 in adults with alpha-1 antitrypsin deficiency-associated lung disease and/or liver disease.
The trial title describes it as a dose-exploration and dose-expansion study, so the researchers are first learning about the best dose and then studying that dose in more people.
Who is being studied
The target population is adult patients with alpha-1 antitrypsin deficiency-related lung disease and/or liver disease. This means the study is not for children and is focused on people whose lungs, liver, or both are affected by this inherited condition.
The condition studied is listed as Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease. In simple terms, alpha-1 antitrypsin deficiency is a genetic disorder, meaning it is passed through families.
Trial phases and study design
This is a Phase 1/2 trial. Phase 1 usually focuses on safety and tolerability, while Phase 2 looks more closely at whether the treatment may help the disease.
The study includes two main parts: Phase 1 (Dose Exploration) and Phase 2 (Dose Expansion). Dose exploration means the researchers are testing and learning which dose is most suitable, and dose expansion means they give that dose to more participants to gather more information.
The planned enrollment is 184 participants. Enrollment is the number of people the study plans to include.
Outcomes being measured
The main goal in Phase 1 is to evaluate safety and tolerability of Gr0015 and to help find the optimal biological dose (the dose that gives the best biological effect for the study).
The primary endpoint in Phase 1 is the rate of treatment-emergent adverse events and serious adverse events. Adverse events are unwanted medical problems seen during the study, and serious adverse events are the more severe ones.
The main goal in Phase 2 is to evaluate efficacy, meaning whether the treatment shows a helpful effect, based on pharmacodynamic activity. Pharmacodynamic activity means changes in the body that suggest the treatment is doing what it is supposed to do in the study.
The Phase 2 primary endpoint is the absolute blood levels of total AAT, Z-AAT, and M-AAT. These are blood measurements the researchers use to track the biological effect of the study treatment.
What the study may show
This trial is designed to answer two main questions: first, whether Gr0015 is safe and tolerable in adults with AATD-related lung and/or liver disease, and second, whether it shows early signs of benefit in the body. The study does not yet provide a final answer about long-term benefit, but it is an important step in early clinical research.
Because the trial includes both dose finding and dose expansion, it may help researchers choose the best dose for later studies if the results are promising.